{"id":49893,"date":"2022-10-20T23:01:37","date_gmt":"2022-10-20T21:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/"},"modified":"2022-10-20T23:01:37","modified_gmt":"2022-10-20T21:01:37","slug":"reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/","title":{"rendered":"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022"},"content":{"rendered":"
\n

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc<\/a>. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich\u2019s ataxia will be presented at the International Congress for Ataxia Research 2022 (\u201cICAR\u201d) being held in Dallas, TX from November 1 \u2013 4, 2022.\n<\/p>\n

<\/a><\/p>\n

\nThe abstracts for the oral and poster presentations are listed below and will be available on the conference website at International Congress for Ataxia Research (ataxiacongress.org)<\/a>.\n<\/p>\n\n\n\n\n\n\n\n\n\n
\n

\nOral Presentation:<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAbstract Title:<\/b> Direct utility of natural history data in analysis of clinical trials: Propensity match-based analysis of Omaveloxolone in Friedreich\u2019s ataxia using the FA-COMS dataset\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter:<\/b> David Lynch, MD, PhD, Director, Friedreich’s Ataxia Program, Division of Neurology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA
\n
Date\/Time:<\/b> November 4, 2022, Late-Breaking Research Session 9:00 AM, Presentation at 9:40 AM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPoster Presentations:<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

Abstract Title:<\/b> Efficacy of Omaveloxolone in Patients with Friedreich\u2019s Ataxia: Delayed-Start Analysis<\/td>\n<\/tr>\n
Presenter:<\/b> David Lynch, MD, PhD, Director, Friedreich’s Ataxia Program, Division of Neurology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA
Date\/Time:<\/b> November 2 and 3, 2022, from 12:00 PM \u2013 2:00 PM<\/td>\n<\/tr>\n
\n

\nAbstract Title:<\/b> Disease Burden in Patients with Friedreich\u2019s Ataxia in the US: Real World Evidence (RWE) Retrospective Claims Analysis\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter:<\/b> Christene Song, Senior Director, Medical & Clinical Strategy, Reata
\n
Date\/Time:<\/b> November 2 and 3, 2022, from 12:00 PM \u2013 2:00 PM\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Friedreich’s Ataxia<\/b>\n<\/p>\n

\nFriedreich\u2019s ataxia is a rare, genetic, life-shortening, debilitating, and degenerative neuromuscular disorder typically caused by a trinucleotide repeat expansion in the first intron of the frataxin gene, which encodes the mitochondrial protein frataxin. Pathogenic repeat expansions can lead to impaired transcription and reduced frataxin expression, which can result in mitochondrial iron overload and poor cellular iron regulation, increased sensitivity to oxidative stress, and impaired mitochondrial ATP production. Patients with Friedreich\u2019s ataxia typically experience symptoms in childhood, including progressive loss of coordination, muscle weakness, and fatigue that commonly results in motor incapacitation with patients requiring a wheelchair in their 20s. Patients with Friedreich\u2019s ataxia may also experience visual impairment, hearing loss, diabetes, and cardiomyopathy. On average, patients with Friedreich\u2019s ataxia die in the mid-thirties. Based on literature and proprietary research, we believe Friedreich\u2019s ataxia affects approximately 5,000 children and adults in the United States and 22,000 individuals globally. There are an estimated 4,000 patients diagnosed with Friedreich\u2019s ataxia in the United States. Currently, there are no approved therapies for the treatment of Friedreich\u2019s ataxia.\n<\/p>\n

\nAbout Omaveloxolone<\/b>\n<\/p>\n

\nOmaveloxolone is an investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease Designations to omaveloxolone for the treatment of Friedreich\u2019s ataxia. The European Commission has granted Orphan Drug designation in Europe to omaveloxolone for the treatment of Friedreich\u2019s ataxia. A New Drug Application for omaveloxolone for the treatment of Friedreich\u2019s ataxia is currently under review by the U.S. Food and Drug Administration.\n<\/p>\n

\nAbout Reata<\/b>\n<\/p>\n

\nReata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata\u2019s two most advanced clinical candidates, omaveloxolone and bardoxolone methyl (\u201cbardoxolone\u201d), target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Omaveloxolone and bardoxolone are investigational drugs, and their safety and efficacy have not been established by any agency.<\/b>\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop, and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as \u201cbelieves,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201caims,\u201d \u201cplans,\u201d \u201cmodel,\u201d and \u201cexpects.\u201d Forward-looking statements are based on Reata\u2019s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata\u2019s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, under the caption \u201cRisk Factors.\u201d The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nReata Pharmaceuticals, Inc.
\n
(972) 865-2219
\n
https:\/\/www.reatapharma.com\/<\/a>\n<\/p>\n

\nInvestor Relations & Media Relations:<\/b>
John Hunter ir@reatapharma.com<\/a>
Wendy Segal media@reatapharma.com<\/a>
https:\/\/www.reatapharma.com\/contact-us\/<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich\u2019s ataxia will be presented at the International Congress for Ataxia Research 2022 (\u201cICAR\u201d) being held in Dallas, TX from November 1 \u2013 4, 2022. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49893","6":"format-standard","7":"category-industry"},"yoast_head":"\nReata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich\u2019s ataxia will be presented at the International Congress for Ataxia Research 2022 (\u201cICAR\u201d) being held in Dallas, TX from November 1 \u2013 4, 2022. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-20T21:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221019005855\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022\",\"datePublished\":\"2022-10-20T21:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/\"},\"wordCount\":945,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005855\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/\",\"name\":\"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005855\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\",\"datePublished\":\"2022-10-20T21:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005855\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005855\\\/en\\\/1133860\\\/21\\\/REATA_PHARM_Normal_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/","og_locale":"en_US","og_type":"article","og_title":"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 - Pharma Trend","og_description":"PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich\u2019s ataxia will be presented at the International Congress for Ataxia Research 2022 (\u201cICAR\u201d) being held in Dallas, TX from November 1 \u2013 4, 2022. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-20T21:01:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221019005855\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022","datePublished":"2022-10-20T21:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/"},"wordCount":945,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005855\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/","url":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/","name":"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005855\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","datePublished":"2022-10-20T21:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221019005855\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221019005855\/en\/1133860\/21\/REATA_PHARM_Normal_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/reata-pharmaceuticals-announces-presentations-at-the-international-congress-for-ataxia-research-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49893"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49893\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}